# ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer

> **NCT05824559** · PHASE1 · TERMINATED · sponsor: **MEI Pharma, Inc.** · enrollment: 23 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** ME-344
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT05824559
- **Lead sponsor:** MEI Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-08-07
- **Primary completion:** 2024-07-09
- **Final completion:** 2024-07-23
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** Company decision to wind down operations, close all clinical programs and evaluate strategic options
- **Last updated:** 2024-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05824559

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05824559, "ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05824559. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*